David Malcom Rodman - 13 May 2024 Form 4 Insider Report for Mineralys Therapeutics, Inc. (MLYS)

Role
Chief Medical Officer
Signature
/s/ Adam Levy, Attorney-in-fact
Issuer symbol
MLYS
Transactions as of
13 May 2024
Net transactions value
+$9,566
Form type
4
Filing time
15 May 2024, 16:43:17 UTC
Previous filing
10 May 2024
Next filing
13 Jun 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MLYS Common Stock Options Exercise $2,710 +5,018 +7.5% $0.5400* 72,015 13 May 2024 Direct
transaction MLYS Common Stock Options Exercise $6,856 +6,348 +8.8% $1.08* 78,363 13 May 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MLYS Stock Option Options Exercise $0 -5,018 -11% $0.000000 40,138 13 May 2024 Common Stock 5,018 $0.5400 Direct F1, F2
transaction MLYS Stock Option Options Exercise $0 -6,348 -3.1% $0.000000 196,706 13 May 2024 Common Stock 6,348 $1.08 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Due to a rounding error, the exercise price for this stock option was originally reported as $0.53 per share on the Reporting Person's Form 3 filed on February 9, 2023.
F2 The stock option vested with respect to 25% of the underlying shares on March 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.
F3 Due to a rounding error, the exercise price for this stock option was originally reported as $1.07 per share on the Reporting Person's Form 3 filed on February 9, 2023.
F4 The stock option vested with respect to 25% of the underlying shares on July 12, 2023, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.